RFG Advisory’s Allena Pharmaceuticals ALNA Stock Holding History

RFG Advisory’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,000	Closed	-$3K	–	604
2022 Q1	$3K	Buy	+11,000	New	+$4.55K	﹤0.01%	508

Other funds holding ALNA

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

RFG Advisory's ALNA Position: Q2 2022 in Review

RFG Advisory sold out of Allena Pharmaceuticals (ALNA) in Q2 2022, closing a stake of 11,000 shares — an estimated $3K sold.

RFG Advisory first reported a position in ALNA in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 25 funds tracked by Wall St. Rank hold ALNA as of Q2 2022.

RFG Advisory reported no remaining Allena Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
RFG Advisory sold 11,000 Allena Pharmaceuticals shares in Q2 2022, an estimated $3K.
RFG Advisory first reported a position in Allena Pharmaceuticals in Q1 2022 and held it in 1 quarter.
RFG Advisory's Allena Pharmaceuticals position peaked at $3K in Q1 2022.
25 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2022.

Based on RFG Advisory's 13F filing for Q2 2022, filed 9 Aug 2022.